JAMA has invited this response from Bayer Corporation
to the article authored by Psaty et al (the “Article”), which
appears on page 2622 in this issue. Although the Article is presented as a
scientific review of facts, sections are copied verbatim from a report submitted
by the lead author in a US lawsuit in which he served as a paid expert for
the plaintiff. Moreover, the Article’s conclusions are based upon selected
exhibits from another lawsuit in which another author (Dr Ray) submitted a
report for plaintiffs. Bayer won that court case (as well as the only other
cerivastatin cases that have gone to trial). At least 2 of the authors continue
to participate in lawsuits against Bayer.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 8
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
With one exception, statins seemed to be relatively safe drugs. A cohort study comparing...
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.